61 results about "Phosphanilic acid" patented technology

Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them.

The invention provides cosmetic compositions containing powders that are surface treated with organophosphonic acid compounds, where the surface treated particulates are simultaneously hydrophobic and lipophilic. The invention also provides (a) methods for preparing cosmetic compositions containing said powders, and (b) methods for preparing cosmetic compositions containing said powders where the powders have been treated via a volatile organic solvent-free manufacturing process.

Metal pigment particles are treated with a product resulting from the reaction between an organic phosphonic acid with an amine having at least one organic group containing at least six carbon atoms to inhibit their reactivity to water. The treated metal particles can be used in coating and ink compositions. Additionally, the treated metal particles can be used to formulate pastes and dispersions that are provided to a coatings manufacturer.

Pharmaceutical compositions for intranasal administration are provided that contain at least one compound of formula (I) or a pharmaceutically acceptable salt thereof:

and one or more pharmaceutically acceptable additives for forming a composition for intranasal administration. Also provided are methods of treating one or more conditions in a mammal associated with a glutamate abnormality that includes administering intranasally to a mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

The invention relates to a novel composition useful as a feed at production of chlorine dioxide, said composition being an aqueous solution comprising from about 1 to about 6.5 moles/liter of alkali metal chlorate, from about 1 to about 7 moles/liter of hydrogen peroxide and at least one of a protective colloid, a radical scavenger or a phosphonic acid based complexing agent, wherein the pH of the aqueous solution is from about 1 to about 4. The invention also concerns a process for producing chlorine dioxide using the novel composition.

The invention provides a compound preparation containing diphosphonic acid compound and vitamin clathrate and a preparation method thereof, and belongs to the technology field of medicines. The compound preparation comprises (wt%) diphosphonic acid compound 5-50 and vitamin D 0.005-0.5, wherein the vitamin D is prepared into clathrate derivative with cyclodextrin, and the weight ratio of vitamin D to clathrate derivative is 1:(100-2,000). The invention provides a simple and practical preparation method for a compound preparation containing alendronate and vitamin D with the improved solubility and stability of vitamin D. The inventive compound preparation has definite therapeutic effect and good safety; and has improved solubility and stability of vitamin D due to clathration of vitamin D with cyclodextrin or derivative thereof, thereby being helpful for controlling content uniformity in case of low dose preparation production and reducing the loss vitamin D raw material during batch charging.

The invention discloses a double phosphonate medicine and a method for the isolation analysis of the ion chromatography for impurity negative ions thereof; the method includes steps of the base line mapping, the sample injection, the ion exchange, the elution and the detection and analysis of the restraining electric conduction; the method can be used to measure the contents of the double phosphonate and the impurity negative ions in double phosphonate medicines, plasmas, normal saline substrates and glucose substrates.

The invention relates to the field of novel biomedical materials, in particular to a bioactive silicon regenerative medical material and a preparation method thereof. The material comprises a scaffoldwhich is formed by accumulating nanoscale silicon dioxide particles and has a porous structure, and calcium and phosphorus elements which are uniformly distributed in the scaffold, and is a calcium phosphosilicate compound with biological activity, wherein the specific surface area is 200-350 m <2>/g; the material is prepared from the following components in percentage by mole: 28.5 to 81 percentof SiO2, 2.7 to 14.0 percent of P2O5 and 16.2 to 57.5 percent of CaO. The material is prepared from the following components in parts by weight: 25 to 75 parts of silicon dioxide sol, 5 to 15 parts of phosphate esters, 0.01 to 0.2 part of a surfactant, 15 to 50 parts of calcium-containing salt and 0.5 to 1.5 parts of a pH regulator. According to the method, the problems that a solvent is requiredto be used in the process of synthesizing the bioactive silicon regenerative medical material by taking tetraethoxysilane and the like as silicon precursors, the solvent is difficult to recover, theproduction period is long, and the corrosion of a catalyst to equipment is large are solved; in addition, the silicon dioxide sol with a large specific surface area is introduced, so that the bioactive silicon regenerative medical material with a larger specific surface area is synthesized, and the biological activity is stronger.

The invention relates to a high-temperature binding agent of aluminum phosphosilicate and a preparation method of the high-temperature binding agent. The high-temperature binding agent comprises aluminum dihydrogen phosphate, silicate, metal and/or metal oxide, phosphoric acid, silica, an organic modifier, natural mineral powder and auxiliaries. Silicate is added into aluminum dihydrogen phosphate and reacts with carbon dioxide in air to form silicic acid sol, inorganic silica chain net-shaped macromolecules are formed along with evaporation and dehydration of water, the toughness of the binding agent is improved, and the brittleness is reduced; the silica and alumina generate mullite at high temperature, and the mullite has the advantages of uniform expansion, excellent thermal shock stability, small high-temperature creep value and high hardness, so that the high temperature resistance and corrosion resistance of the binding agent are improved; and the organic modifier has good film-forming property, and the formed film has excellent adhesive force, so that the film-forming property of the high-temperature adhesive at normal temperature can be improved.

The invention belongs to the technical field of a dental biological medical material and particularly relates to a tooth desensitizer containing phosphosilicate glass as well as a preparation method and application thereof. After the phosphosilicate glass is contacted with a phosphate buffer solution, artificial saliva or simulated body fluid, phosophate ions as well as calcium, strontium, magnesium, zinc, potassium or sodium ions can be released rapidly, a SiO2-enriched silica gel layer is formed on the surface of a material, Ca<2+> and PO4<3-> form a CaO-P2O5 amorphous layer on the SiO2 silica gel layer and the CaO-P2O5 amorphous layer is crystallized to be transformed into hydroxyapatite (HA), so that a dentinal tubule is rapidly closed and hemodia is treated. After the phosphosilicateglass and composite resin are compounded, the phosphosilicate glass is rapidly photocured through photo-initiated polymerization curing to cover the surface of a tooth, so that the dentinal tubule canbe closed rapidly and the hemodia is treated. The tooth desensitizer can block the dentinal tubule rapidly and effectively and induce a dentin layer to be rapidly repaired.

The invention belongs to the field of medical chemistry, relates to phosphonic acid derivatives for treating virus infectious diseases and an application thereof, and in particular, relates to the compounds represented by the formula (I) or isomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method thereof, pharmaceutical compositions containing the compounds and an application of the compounds or the compositions in preparation of drugs for treating the virus infection diseases.

Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. Although an oral dosage form with enhanced bioavailability with respect to the bisphosphonate compound can be used, the treatment can also be effective using an oral dosage form that includes a bisphosphonate compound, such as zoledronic acid, wherein the bioavailability of the bisphosphonate is unenhanced, or is substantially unenhanced.

A reinforced bone china for daily use and a preparing method thereof are disclosed. The bone china for daily use is prepared from, by mass, 1-3 parts of an additive ZL, 40-45 parts of bone char, 10-12 parts of quartz, 10-12 parts of feldspar, 24-28 parts of kaolin, 48-52 parts of water, 1-3 parts of a crystal form improving agent, 1-2 parts of a mineralizer and 1-3 parts of a phosphosilicate targeting fluxing agent. Through scientifically introducing the phosphosilicate targeting fluxing agent, introduction of potassium-containing and sodium-containing mineral raw materials is significantly reduced, and the sintering temperature and the expansion coefficient of a blank are controlled well. Through introducing the additive ZL, the crystal form improving agent and the mineralizer into bone china pug, uniform crystal growth in a stage of vitrification to form the china is ensured, a phosphosilicate glass phase network is further complete, and mechanical strength and thermal shock resistance of the bone china are finally improved. The bone china for daily use is high in mechanical strength, smooth in glaze, easy to clean, significantly reduced in lead and cadmium dissolving-out amounts, and good in thermal shock resistance.

The invention discloses a phosphosilicate type rare earth ore flotation collector and a preparation method and an application thereof. The phosphosilicate type rare earth ore flotation collector is prepared from the following materials according to the mass ratio: 5 to 15 parts of octyl ether propyl-a-amino-1,1-diphosphonic acid, 60 to 80 parts of dist coconut fatty acid, 5 to 10 parts of hexadecyl sulfonate and 1 to 3 parts of Tween-60. The phosphosilicate type rare earth ore flotation collector has the advantages of high collecting capability, high concentrate recovery rate, low production cost, less consumption and good separation effect when the phosphosilicate type rare earth ore flotation collector is applied to the floatation of phosphosilicate type rare earth ore or xenotime.

The invention relates to a novel imidazole diphosphonie acid compound and a pharmaceutically-acceptable salt thereof. The diphosphonie acid compound disclosed by the invention, farnesylpyrophosphate synthetase is treated, and lipotropy is enhanced. The type of compound can be used for treating diseases including osteoporosis, hypercalcinemia and the like, and can be applied to cancer chemotherapy, immunotherapy and the like.

The invention discloses an oral pharmaceutical composition containing bisphosphates and a preparation method thereof, wherein the oral pharmaceutical composition comprises bisphosphates drugs, a metal-ion complexing agent and other pharmaceutically acceptable drug carriers. The composition has good stability and pharmacokinetics property and is applied to the treatment of bone diseases and certain metabolic calcium disorders.

The invention discloses a dyeing and flame-retardant finishing method for a wool suit fabric. The method comprises the two steps of dyeing and flame-retardant finishing, wherein a reactive dye is adopted for dyeing, and an active component of a flame-retardant finishing agent is beta-(N-phenylamide) ethylmethyl phosphinic acid. According to the dyeing and flame-retardant finishing method for the wool suit fabric, the reactive dye is adopted for dyeing, the beta-(N-phenylamide) ethylmethyl phosphinic acid containing nitrogen and phosphorus and having reaction activity is adopted as the active component of the flame-retardant finishing agent, the flame-retardant active component is crosslinked with a wool molecular chain, the obtained wool suit fabric has a similar semi-permanent flame-retardant effect, and the dyeing color depth K/S value is reduced by 15% or below.

There is provided herein a process for preparing cyclic phosphonate ester comprising reacting a glycol with at least one of phosphonic acid and phosphinic acid in the presence of a solvent. There is also provided a flame retardant comprising the cyclic phosphonate ester and industrial applications containing a flame retardant effective amount of the cyclic phosphonate ester.

The present invention relates to diphosphonic acid derivative, and 99mTc labeled diphosphonic acid derivative ligand or the label obtained through labeling diphosphonic acid derivative ligand and coligand. The label may be used in preparing developer for human and animal organs, especially bone.

The invention discloses random polymers with a framework containing ammonium and phosphonic acid groups, and a preparation method thereof. According to the method, a dihalide monomer containing amino group, a dihalide monomer containing phosphonic acid group, and a diphenol monomer (or dithiol monomer) are mixed according to a certain ratio; under the existence of a medium-strong alkali and toluene, in a high-boiling-point aprotic solvent, the temperature is increased to a certain value, and a reaction is carried out; an obtained viscous material is treated, such that a polymer containing amino group and phosphinic acid group is obtained. The polymers are subjected to acidification and heating treatments, such that high-molecular materials with a framework containing zwitterionic groups is obtained. The novel random polymers show good nano-filtration/reverse osmosis desalination properties, and can be applied in the field of water treatment.

The invention relates to a preparation method of dialkyl phosphinic acid. The preparation method comprises the following steps: mixing magnesium metal, halohydrocarbon and a first solvent and carrying out a reaction to obtain a Grignard reagent; adding phosphorus oxychloride into the Grignard reagent and carrying out a reaction to obtain a dialkyl phosphoryl chloride coarse product; and adding an organic acid to hydrolyze dialkyl phosphoryl chloride in the dialkyl phosphoryl chloride coarse product to dialkyl phosphinic acid.

The invention discloses a 1-calcium phosphate-uracil mixed liquor and its preparation method and application. The 1-calcium phosphate-uracil mixed liquor is mainly made from the following components of: by weight, 16-25 parts of 1-calcium phosphate-uracil, 30-50 parts of dipotassium hydrogen phosphate, 1-3 parts of potassium nitrate, 4-6 parts of ammonium nitrite, 12-14 parts of acrylic acid and 6-8 parts of propanenitrile. Special effects of the invention are shown as follows: a terminal liquid (a by-product), namely the 1-calcium phosphate-uracil mixed liquor, which is generated from the preparation of 1-calcium phosphate-uracil, is used in green agriculture production, and the 1-calcium phosphate-uracil mixed liquor is used for breeding and sprinkling target plants, so as to promote seed differentiation and germination, raise effective tillering rate and soundness of paddy rice and wheat, reduce the dosage and residual quantity of pesticides, prevent freezing and resist lodging, increase the output and quality of paddy rice and target plants, enable the output of paddy rice to increase by over 6%, protect ecological environment and improve food source safety.

The invention discloses a preparation method for a propolis acne-removing balance base solution. The preparation method comprises the following steps: (1) an emulsifying pot is cleaned and then disinfected for later use; (2) 50 parts of water and 16.5 parts of calcium phosphosilicate are poured into the emulsifying pot, are uniformly stirred, and are heated to 85 DEG C; (3) water temperature is kept at 85 DEG C, 5 parts of propolis extract, 15 parts of glycerol and 13 parts of propylene glycol are sequentially added while stirring is performed, a mixed solution is obtained after complete dissolving, and heat preservation is performed on the mixed solution at 85 DEG C for 40 minutes; and (4) heat preservation is stopped, when the mixed solution in the emulsifying pot is cooled to 50 DEG C,0.1 part of o-cymene-5-alcohol, 0.3 part of 1,2-hexanediol and 0.1 part of ethylhexylglycerin are added into the emulsifying pot while stirring is performed, and after uniform stirring, slow cooling is performed to 37 DEG C to obtain the propolis acne-removing balance base solution. The invention further discloses the propolis acne-removing balance base solution prepared by the method.